{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:58:54Z","timestamp":1782471534373,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7212101"],"award-info":[{"award-number":["7212101"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Science and Technology Special Project of China","award":["2018ZX10725-506"],"award-info":[{"award-number":["2018ZX10725-506"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00535-023-01970-3","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:51:13Z","timestamp":1679874673000},"page":"481-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4961-8560","authenticated-orcid":false,"given":"Xiujuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laicheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-4308","authenticated-orcid":false,"given":"Yongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-1095","authenticated-orcid":false,"given":"Yongping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"1970_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","volume":"71","author":"C P\u00e9neau","year":"2022","unstructured":"P\u00e9neau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022;71:616\u201326.","journal-title":"Gut"},{"key":"1970_CR2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/jgh.12213","volume":"28","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013;28:912\u201323.","journal-title":"J Gastroenterol Hepatol"},{"key":"1970_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/infdis\/jiaa266","volume":"225","author":"G Rong","year":"2022","unstructured":"Rong G, Chen Y, Yu Z, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2022;225:1091\u20139.","journal-title":"J Infect Dis"},{"key":"1970_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41401-022-00874-x","volume":"43","author":"XF Tong","year":"2022","unstructured":"Tong XF, Wang QY, Zhao XY, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43:1200\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"1970_CR5","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jhep.2020.08.014","volume":"73","author":"EM Brunt","year":"2020","unstructured":"Brunt EM. Liver biopsy reliability in clinical trials: thoughts from a liver pathologist. J Hepatol. 2020;73:1310\u20132.","journal-title":"J Hepatol"},{"key":"1970_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/apt.14529","volume":"47","author":"T Karlas","year":"2018","unstructured":"Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther. 2018;47:989\u20131000.","journal-title":"Aliment Pharmacol Ther"},{"key":"1970_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jhep.2015.11.012","volume":"64","author":"WR Kim","year":"2016","unstructured":"Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773\u201380.","journal-title":"J Hepatol"},{"key":"1970_CR8","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jhep.2013.01.028","volume":"58","author":"M Martinot-Peignoux","year":"2013","unstructured":"Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e antigen-positive patients. J Hepatol. 2013;58:1089\u201395.","journal-title":"J Hepatol"},{"key":"1970_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043087","volume":"7","author":"WK Seto","year":"2012","unstructured":"Seto WK, Wong DK, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7: e43087.","journal-title":"PLoS One"},{"key":"1970_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","volume":"65","author":"T Tada","year":"2016","unstructured":"Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics. J Hepatol. 2016;65:48\u201356.","journal-title":"J Hepatol"},{"key":"1970_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni B, Leboss\u00e9 F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615\u201325.","journal-title":"J Hepatol"},{"key":"1970_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77:42\u201354.","journal-title":"J Hepatol"},{"key":"1970_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/gutjnl-2014-306977","volume":"64","author":"TC Tseng","year":"2015","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64:292\u2013302.","journal-title":"Gut"},{"key":"1970_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1128\/JCM.41.3.1277-1279.2003","volume":"4","author":"HL Chan","year":"2003","unstructured":"Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol. 2003;4:1277\u20139.","journal-title":"J Clin Microbiol"},{"key":"1970_CR15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/1745-6215-15-438","volume":"15","author":"J Qu","year":"2014","unstructured":"Qu J, Yu Z, Li Q, et al. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials. 2014;15:438.","journal-title":"Trials"},{"key":"1970_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","volume":"77","author":"D Ji","year":"2022","unstructured":"Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022;77:1515\u201324.","journal-title":"J Hepatol"},{"key":"1970_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380.","journal-title":"Hepatology"},{"key":"1970_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England). 2013;381:468\u201375.","journal-title":"Lancet (London, England)"},{"key":"1970_CR19","volume-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"WHO Guidelines Approved by the Guidelines Review Committee","year":"2015","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015."},{"key":"1970_CR20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017\u201344.","journal-title":"Hepatology"},{"key":"1970_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u20139.","journal-title":"J Hepatol"},{"key":"1970_CR22","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1128\/JCM.00366-07","volume":"45","author":"DK Wong","year":"2007","unstructured":"Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942\u20137.","journal-title":"J Clin Microbiol"},{"key":"1970_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","volume":"40","author":"T Kimura","year":"2002","unstructured":"Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439\u201345.","journal-title":"J Clin Microbiol"},{"key":"1970_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00535-010-0315-4","volume":"46","author":"Z Xu","year":"2011","unstructured":"Xu Z, Ren X, Liu Y, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol. 2011;46:391\u2013400.","journal-title":"J Gastroenterol"},{"key":"1970_CR25","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","volume":"20","author":"I Graupera","year":"2022","unstructured":"Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20:2567-2576.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1970_CR26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2017.01.003","volume":"66","author":"J Boursier","year":"2017","unstructured":"Boursier J, de Ledinghen V, Leroy V, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158\u201365.","journal-title":"J Hepatol"},{"key":"1970_CR27","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3748\/wjg.v25.i32.4764","volume":"25","author":"XJ Chang","year":"2019","unstructured":"Chang XJ, Sun C, Chen Y, et al. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol. 2019;25:4764\u201378.","journal-title":"World J Gastroenterol"},{"key":"1970_CR28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/v13060951","volume":"13","author":"A Vachon","year":"2021","unstructured":"Vachon A, Osiowy C. Novel biomarkers of hepatitis B virus and their use in chronic hepatitis B patient management. Viruses. 2021;13:951.","journal-title":"Viruses"},{"key":"1970_CR29","doi-asserted-by":"publisher","first-page":"3890962","DOI":"10.1155\/2019\/3890962","volume":"2019","author":"W Wang","year":"2019","unstructured":"Wang W, Shu Y, Bao H, et al. Genotypes and hot spot mutations of hepatitis B virus in northwest Chinese population and its correlation with diseases progression. Biomed Res Int. 2019;2019:3890962.","journal-title":"Biomed Res Int"},{"key":"1970_CR30","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/bjc.2012.474","volume":"107","author":"CM Chu","year":"2012","unstructured":"Chu CM, Lin CC, Chen YC, et al. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer. 2012;107:2010\u20135.","journal-title":"Br J Cancer"},{"key":"1970_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441\u201350.","journal-title":"Hepatology"},{"key":"1970_CR32","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1478-3231.2010.02267.x","volume":"30","author":"CM Croagh","year":"2010","unstructured":"Croagh CM, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010;30:1115\u201322.","journal-title":"Liver Int"},{"key":"1970_CR33","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.14309\/ajg.0000000000001239","volume":"116","author":"D Ji","year":"2021","unstructured":"Ji D, Chen Y, Shang Q, et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B. Am J Gastroenterol. 2021;116:1676\u201385.","journal-title":"Am J Gastroenterol"},{"key":"1970_CR34","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1053\/j.gastro.2019.08.028","volume":"157","author":"TC Tseng","year":"2019","unstructured":"Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157:1518-29.e3.","journal-title":"Gastroenterology"},{"key":"1970_CR35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00535-020-01700-z","volume":"55","author":"LY Liang","year":"2020","unstructured":"Liang LY, Wong VW, Toyoda H, et al. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol. 2020;55:899\u2013908.","journal-title":"J Gastroenterol"},{"key":"1970_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.15108","volume":"49","author":"T Hosaka","year":"2019","unstructured":"Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2019;49:457\u201371.","journal-title":"Aliment Pharmacol Ther"},{"key":"1970_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00535-021-01780-5","volume":"56","author":"LY Mak","year":"2021","unstructured":"Mak LY, Huang Q, Wong DK, et al. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2021;56:479\u201388.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01970-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-01970-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01970-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T12:12:30Z","timestamp":1682597550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-01970-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1970"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-01970-3","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest concerning this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}